Saturday November 21 2009 | Biotechnology feed | All feeds
|
|
|
Cypress Bioscience
Download detailed PDF Members: We are committed to being the innovator and leader in providing products for the treatment of patients with Functional Somatic Syndromes, such as Fibromyalgia Syndrome, or FMS, and other central nervous system disorders. Specifically, our strategy involves acquiring or in-licensing central nervous system, or CNS, active compounds and developing them for novel and typically underserved indications. The term Functional Somatic Syndromes refers to several related syndromes characterized more by symptoms, suffering and disability than by disease specific abnormalities that are found upon physical examination and include many overlapping pain and psychiatric conditions. We find these opportunities in the areas in which the brain and body overlap, where CNS mechanisms have a strong influence on somatic or bodily symptoms, particularly interesting, and our ongoing development program at Cypress, evaluating milnacipran as a potential treatment for FMS, is representative of this strategy. Our goal is to be the first to commercialize a product approved in the United States for the treatment of Fibromyalgia Syndrome, or FMS, the focus of our initial efforts in the area of Functional Somatic Syndromes. In January 2004, we entered into a collaboration agreement with Forest Laboratories, Inc., a leading marketer of central nervous system drugs with a strong franchise in the primary care and psychiatric markets, for the development and marketing of milnacipran. After completing a successful Phase II trial, we commenced the first Phase III trial for milnacipran in October 2003. Enrollment in this trial was completed in December 2004, with results announced in September 2005. In October 2004, Forest Laboratories initiated the second Phase III trial evaluating milnacipran for the treatment of FMS. Additionally, we and Forest commenced our third Phase III trial evaluating milnacipran as a treatment for FMS in the first quarter of 2006. We completed the first pivotal Phase III trial evaluating milnacipran for the treatment of FMS in July of 2005. The Phase III trial was a six month, randomized, placebo-controlled study involving 50 sites and 888 FMS patients who were randomized to either milnacipran treatment or placebo. The preliminary top-line results of the study support the continued development of milnacipran as a treatment for fibromyalgia. Although the results of the trial did not achieve statistical significance at the p<0.05 level, the planned development program for milnacipran, which includes two ongoing Phase III studies, will continue. We obtained an exclusive license for milnacipran from Pierre Fabre Medicament in 2001. Milnacipran has been marketed outside of the United States since 1997 as an antidepressant and has been used by over 3,000,000 patients worldwide. Milnacipran is the first of a new class of agents known as norepinephrine serotonin reuptake inhibitors, or NSRIs, which increase the level of norepinephrine more than they do serotonin. We are continuing to evaluate other various potential strategic transactions, including the potential acquisitions of products, technologies and companies, and other alternatives.
This page has been viewed 595 times since April 2007, the link to the organisation's website has been followed 84 times Recent Search Terms used to find this page: cypress bioscience cns | F2695 FMS | functional somatic syndrome list | fibromyalgia conference 2009 | . Search for more companies in San Diego Search for more companies in CA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for Cypress Bioscience | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Nothing in this website should be used in
place of personal medical advice from your own qualified medical
practitioner. |
All rights reserved. All other trademarks recognized. |
|
